Joe McCann

Partner, Beta Partners GP

Joe McCann is an experienced biotech leader with 18 years of experience, spanning roles from start-up to big pharma. For the past 14 years, he has specialized in targeted oncology, particularly in radioligand therapies and imaging (Theranostics). In late 2019, Joe co-founded POINT Biopharma Inc. a company focused on the discovery and development of radioligand therapies. As CEO, he guided the company through early and late-stage asset development, managed in- and out-licensing deals, raised over $650 million through both dilutive and non-dilutive financings, and took POINT public on NASDAQ in July 2021. In December 2023, Eli Lilly acquired POINT for $1.4 billion. Today, Joe serves as Senior Vice President in Lilly’s Oncology organization, driving the integration of the Radioligand Therapy Platform into Lilly’s oncology pipeline. Joe has also co-founded an investment fund, Beta Partners GP, with the co-founders of POINT.

Prior to POINT, Joe held progressively senior roles at the Centre for Probe Development and Commercialization (CPDC) starting in 2010, culminating as CEO and President. At CPDC, he expanded the theranostic manufacturing platform, building out contract development and manufacturing operations, positioning the organization as a leader in the field (now known as AtomVie). Earlier in his career, Joe worked as a Scientist in Pharmaceutical Development at GlaxoSmithKline, supporting clinical product development across all phases.

He holds a Ph.D. in Biochemistry from McMaster University, where his research focused on the transition state analysis of enzyme-catalyzed reactions, and a B.Sc. in Biochemistry from the University of Guelph.